A cost-effectiveness analysis of empagliflozin for heart failure patients across the full spectrum of ejection fraction in Spain: combined results of the EMPEROR-Preserved and EMPEROR-Reduced trials

CONCLUSIONS: Empagliflozin is the first treatment with established efficacy and cost-effectiveness for HF patients across EF from the perspective of healthcare payers in Spain. Empagliflozin also proved to be cost-effective for all subgroups of patients included in the analysis.PMID:38416135 | DOI:10.1080/14779072.2024.2324027

Source: Expert Review of Cardiovascular Therapy - February 28, 2024 Category: Cardiology Authors: Xavier Garc ía-Moll Francesco Croci Alexandra Sol é Elisabeth S Hartgers-Gubbels Miguel A Calleja-Hern ández Source Type: research